Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimedat and Rebagit in Irritable Bowel Syndrome and Functional Dyspepsia
NCT05379036Phase 4Unknown
- Sponsor
- Sechenov First Moscow State Medical University
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trimebutine, rebamipide in Irritable bowel syndrome with diarrhea (IBS-D), functional dyspepsia (FD), sponsored by Sechenov First Moscow State Medical University. Status: unknown.
02
Drugs
trimebutinerebamipide
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT05379036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379036.